ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.
A panel of mAbs were generated against the purified soluble form of erbB2/Her2 receptor, corresponding to the extracellular region of the receptor, and examined for their ability to mimic the receptor ligand. Some of the mAbs strongly induced tyrosine phosphorylation of 180-185 kDa proteins, including not only Her2 but also Her3 and Her4 receptors, when they were expressed on the surface of breast cancer cells. These mAbs do not cross-react with Her3 or Her4 as demonstrated by competition study. Receptor phosphorylation was also observed with the cell lines transfected with Her2 or a chimeric receptor consisting of the extracellular domain of Her2 and the transmembrane and cytoplasmic domains of epidermal growth factor receptor. Selected mAbs were tested for their ability to change cell morphology, and one specific mAb, mAb74, induced cell morphology changes and apoptosis.
Kita
Y
Y
Department of Immunology, Amgen Inc., Amgen Center, Thousand Oaks, California 91320, USA.
Tseng
J
J
Horan
T
T
Wen
J
J
Philo
J
J
Chang
D
D
Ratzkin
B
B
Pacifici
R
R
Brankow
D
D
Hu
S
S
Luo
Y
Y
Wen
D
D
Arakawa
T
T
Nicolson
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D017209:Apoptosis / Q000276:immunology*; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D066246:ErbB Receptors / Q000378:metabolism*; D010766:Phosphorylation; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D020893:Receptor, ErbB-3; D011994:Recombinant Proteins / Q000276:immunology; D014443:Tyrosine / Q000378:metabolism
D000911:Antibodies, Monoclonal; D066246:ErbB Receptors; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D011994:Recombinant Proteins; D014443:Tyrosine